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Outcome measure Evidence Implications
Patient-oriented evidence
Improved quality of life Substantial Using various rating scales IG was found to be better than NPH insulin in type 1 patients, and better
than pioglitazone and rosiglitazone in type 2 patients
Improved patient satisfaction Substantial Patient acceptance and wellbeing was frequently reported and confirmed in a number of RCTs
Disease-oriented evidence
Effective glycemic control in type 1 diabetes Clear IG is at least as effective as NPH insulin
Lower incidence of hypoglycemia in 
type 1 diabetes
Substantial Trend in many studies was for a lower incidence with IG than with NPH
Effective glycemic control in type 2 diabetes Clear IG was at least as effective as NPH insulin, other insulin regimens, and rosiglitazone or pioglitazone
Lower incidence of hypoglycemia in 
type 2 diabetes
Clear Significantly less hypoglycemia with IG than with NPH insulin
Economic evidence
Cost effectiveness in type 1 diabetes Clear A number of RCTs and large observational studies have established the cost effectiveness of IG and
confirmed its superiority over NPH insulin
Cost effectiveness as add-on therapy in 
type 2 diabetes
Clear The cost effectiveness of IG was superior to that of NPH insulin. It was also associated with lower
total costs for maintaining glycemic control than add-on therapy with rosiglitazone or pioglitazone
IG, insulin glargine; NPH, neutral protamine hagedorn; RCT, randomized controlled trial.
Core evidence clinical impact summary for insulin glargine in the management of type 1 and type 2
diabetes mellitus
Abstract
Introduction: Diabetes is a chronic disease associated with high morbidity and mortality, which represents a major public health
concern. Interventions that can enhance patient care and reduce clinic visits will not only relieve some of this burden, they will also
improve patient QOL and wellbeing.
Aims: This review assesses the evidence for the use of insulin glargine in type 1 and type 2 diabetes mellitus.
Evidence review: Once-daily insulin glargine has a prolonged, peakless activity profile, making it a candidate as a long-acting (basal)
insulin. In combination with bolus insulin to cover prandial glucose surges, it facilitates a more physiologic approach to patient
management. Evidence from large, randomized, controlled clinical trials in patients with type 1 diabetes has confirmed its effectiveness
and tolerability relative to neutral protamine hagedorn (NPH) insulin, with a tendency toward causing less hypoglycemia. In patients with
type 2 diabetes requiring insulin therapy, once-daily insulin glargine has proven to be clinically superior to NPH insulin in terms of
providing at least as effective glycemic control, but with significantly fewer episodes of nocturnal hypoglycemia. A variety of economic
analyses have confirmed the cost effectiveness of insulin glargine in type 1 and type 2 diabetes and in particular it was shown to be
significantly superior to NPH insulin.
Clinical value: Insulin glargine has established itself as a first-line choice in patients with type 1 diabetes, including children (>6 years)
and adolescents, and is a recommended treatment option. In patients with type 2 diabetes it is clearly associated with less hypoglycemia
than NPH insulin, and this may help overcome one of the major barriers to starting insulin therapy in this class of patient. Thus, insulin
glargine is a valuable addition to the therapeutic armamentarium available to physicians and it has the potential to significantly improve
the quality of life of patients with diabetes.
Core Evidence. 2007;2(2):89–110.
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 Scope, aims, and objectives 
Insulin replacement therapy has been a mainstay of treatment
for patients with type 1 diabetes and a third-line alternative in
patients with type 2 disease unresponsive to diet/exercise and
oral antidiabetic drugs. However, traditional insulin products and
more recently introduced intermediate and longer-acting
preparations have not provided consistent metabolic control
over a 24-hour period, while at the same time avoiding the risk
of hypoglycemia (which is a significant cause of morbidity,
particularly at night). The introduction of longer-acting insulin
analogs that more closely mimic endogenous basal insulin
patterns has been facilitated by recombinant DNA technology.
In combination with the development of rapid-acting analogs
that can provide mealtime cover, the newer insulin products
permit greater flexibility with regards to treatment regimens and
the potential to more closely mimic endogenous insulin
release/blood levels (Owens et al. 2000; Gummerson 2006).
Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin;
Lantus®) is an analog of human insulin produced by
recombinant DNA technology using a nonpathogenic strain of
Escherichia coli (K12). Once-daily subcutaneous insulin glargine
has a prolonged duration of action without significant peaks of
activity making it an ideal candidate as a long-acting (basal)
insulin (Heinemann et al. 2000; Lepore et al. 2000; Owens et al.
2000; Luzio et al. 2003). The objective of this article is to review
the current evidence concerning the effectiveness of insulin
glargine in the clinical management of patients with type 1 or
type 2 diabetes mellitus.
Methods
PubMed (http//www.ncbi.nlm.nih.gov/entrez/query.fcgi, from
1966 to date) was searched for “insulin glargine” and “HOE 901”
on November 8, 2006 and updated March 10, 2007 with the limits
“English language,” “randomized controlled trial,” “meta analysis,”
“humans.” In addition, relevant randomized controlled clinical
trials presented at the 2006 European Association for the Study 
of Diabetes (EASD) meeting have been included. The resulting
records were then hand searched and any that did not meet the
following criteria were excluded:
• Insulin glargine versus neutral protamine hagedorn (NPH) in
≥100 patients with type 1 diabetes
• Insulin glargine versus continuous insulin infusion in patients
with type 1 diabetes
• Insulin glargine versus NPH in ≥200 patients with type 2
diabetes 
• Insulin glargine versus premixed human biphasic insulin in
patients with type 2 diabetes
• Insulin glargine versus oral antidiabetic drugs in patients with
type 2 diabetes
• Insulin glargine versus insulin detemir in patients with type 1 
or type 2 diabetes
• Large observational studies or intensive treatment dosage
titration investigations involving >1000 patients with 
type 2 diabetes.
The results of the literature search and selection are shown
in Table 1.
Disease overview
The prevalence of diabetes mellitus has risen dramatically over
the last two decades and the International Diabetes Federation
(IDF) has recently estimated that there are almost 250 million
people with the disease worldwide; this number is projected 
to exceed 380 million by the year 2025 if urgent action is not 
taken (IDF 2007a). Geographically there is a wide variation in 
the incidence of type 1 and type 2 diabetes with the latter
accounting for about 85–95% of cases in developed countries
and a higher proportion in developing countries. Type 2 diabetes
is largely the result of poor diet, excess bodyweight, and physical
inactivity. There is also an association with age (the disease was
previously termed “maturity-onset diabetes”), family history, and
race/ethnicity. Worryingly, there is an increasing prevalence of
type 2 diabetes in children and adolescents, which is fast being
recognized as a global health problem (Pinhas-Hamiel & Zeitler
2005). Type 1 diabetes accounts for approximately 5–10% of all
cases and usually starts in childhood, although onset can occur
at any age. A third form of the disease is gestational diabetes,
which falls outside of the scope of this review.
The burden of diabetes on healthcare systems worldwide is
enormous and this is reflected in prevalence data presented by
the IDF, which estimates that each year 3.8 million deaths are
attributable to the disease and an even greater number of patients
die from cardiovascular disease that is exacerbated by comorbid
diabetes mellitus (IDF 2007a). Additional relevant and startling
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Category Number 
Initial search 59
records excluded 14
records included 45
Additional studies identified 4
Search update, new records 41
records excluded 17
records included 24
Level 1 clinical evidence (systematic review, meta analysis) 1
Level 2 clinical evidence (RCT) 59
Level ≥3 clinical evidence 6
trials other than RCT 6
case reports 0
Economic evidence 7
Total records included 73
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review91
statistics presented by the IDF include: diabetes is the fourth
leading cause of death worldwide; it affects about 6% of the
global adult population; 50% of cases remain undiagnosed (as
high as 80% in some countries); it is the most frequent comorbid
condition associated with kidney failure (10–20% of diabetics die
of renal failure); and diabetic retinopathy is the leading cause of
vision loss in adults aged 20–65 years.
Diabetes mellitus represents a heterogeneous group of metabolic
disorders which are characterized by hyperglycemia as a result of
severe insulin deficiency (type 1 diabetes) or defects in insulin
resistance, impaired insulin secretion, and increased glucose
production (type 2 diabetes). Several distinct forms of diabetes
exist, resulting from a complex interaction of genetics,
environmental factors, and lifestyle choices (Powers 2005).
Diabetes is often associated with comorbidities, such as
hypertension, diabetic nephropathy, dyslipidemia, and thrombotic
abnormalities such as impaired fibrinolysis and platelet
hyperreactivity. When viewed as a whole they represent a milieu
of risk factors that go some way to explaining why
atherothrombosis (e.g. myocardial infarction, ischemic stroke) is
the leading cause of mortality in patients with type 2 diabetes.
They also highlight the need for a holistic approach to managing
such patients with major goals that include establishing tight
metabolic control, normalization of blood pressure and lipid
levels, preservation of renal function, improvement of fibrinolytic
activity, and cessation of smoking.
The Diabetes Control and Complications Trial Research Group
(DCCT Research Group 1993) and the UK Prospective Diabetes
Study (UKPDS 1998a,b) provide convincing evidence that tight
and sustained management of glycemia (HbA1c to ≤7%), using an
intensive therapy regimen and regular follow-up/monitoring,
reduces both the development and progression of microvascular
complications. In the DCCT trial, for example, intensive therapy
reduced microalbuminuria by 39%, albuminuria by 54%, and
clinical neuropathy by 60%. The drawback was an increased
incidence of hypoglycemia which is the single biggest barrier to
administering higher dosages of insulin. Longer-term follow-up 
of 93% of patients included in the DCCT trial over a period of 
17 years showed that intensive therapy reduced the risk of 
any cardiovascular disease events by 42% (P=0.02) and the 
risk of nonfatal myocardial infarction, stroke, or death from
cardiovascular disease by 57% (P=0.02) (Nathan et al. 2005). 
Current therapy options
The major aims of treatment for patients with type 1 or type 2
diabetes mellitus are to provide a level of glycemic control similar
to that of nondiabetic individuals, to eliminate or delay the
development of microvascular/macrovascular complications, and
to minimize debilitating episodes of hypoglycemia and thus
improve quality of life (QOL). Most treatment guidelines are now
built upon the premise that tight management of blood glucose
levels is pivotal to achieve optimal patient care (Powers 2005; 
IDF 2007b). As noted previously, however, management of the
diabetic patient is not simply a matter of treating the metabolic
abnormality, and a holistic approach is required to minimize
cardiovascular risk, diabetic nephropathy, and diabetic
retinopathy. Irrespective of the type of diabetes it is important that
management programs are individualized, taking into account
patient characteristics and needs, as well as medical, social,
nutritional, and lifestyle issues. For patients with type 1 diabetes
mellitus (and therefore minimal or zero endogenous insulin
secretory capacity), replacement insulin is a prerequisite for
survival. Ideally, the replacement regimen should mimic a
“normal” 24-hour insulin profile. In type 2 diabetes, diet, exercise,
and oral antidiabetic drugs are the cornerstone of treatment.
However, if glycemic control cannot be achieved using these
measures, then insulin therapy should be considered, either in
addition to, or in place of, oral antidiabetic drugs. 
Traditional insulin products have generally proven to be
suboptimal with regards to providing a consistent level of
hormone for maintaining metabolic balance over a 24-hour
period, while at the same time limiting the development of
adverse effects such as hypoglycemia. Intermediate and longer-
acting preparations have been developed allowing less-frequent
administration through complexing with zinc (lente and ultralente
insulin) or protamine (NPH) which helps delay the absorption of
insulin. However, these products still have pronounced peaks
following subcutaneous injection and may be associated with
episodes of hypoglycemia. Furthermore, their duration of action
may be too short to allow full 24-hour cover with once-daily
administration. The introduction of longer-acting insulin analogs
which more closely mimic endogenous basal insulin patterns has
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Generic name Brand name Form
Rapid-acting Onset: within 15 mins Duration: up to 4 h
Insulin aspart Novolog, NovoRapid Analog
Insulin glulisine Apidra Analog
Insulin lispro Humalog Analog
Short-acting Onset: within 1 h Duration: up to 18 h
Regular human insulin Humulin R, Novolin R Human
Biphasic insulin analogs Onset: 5–45 min Duration: 10–16 h
Insulin lispro 25%/insulin
lispro protamine 75%
HumalogMix 25 Analog
Insulin lispro 50%/insulin
lispro protamine 50%
HumalogMix 50  Analog
Insulin aspart 30%/insulin
aspart protamine 70% 
NovoMix 30 Analog
Intermediate-acting Onset: 2–4 h Duration: 10–16 h
Human NPH insulin Humulin N, Novolin N Human
Long-acting Onset: 2–4 h Duration: up to 24 h
Insulin detemir Levemir Analog
Insulin glargine Lantus Analog
NPH, neutral protamine hagedorn.
Table 2 | Commonly used human and analog insulins (adapted
from Profit 2005; Gummerson 2006; ADA 2007)been facilitated by recombinant DNA technology. In combination
with the development of rapid-acting analogs which can be used
to provide mealtime cover, the newer insulin products permit
greater flexibility regarding treatment regimens and the potential
to more closely mimic endogenous insulin release/blood levels
(Owens et al. 2000; Gummerson 2006). Several types of human
insulin and insulin analogs with different onsets and durations of
activity are currently available (Table 2).
Clinical efficacy of insulin glargine 
Clinical trials with insulin glargine in patients with diabetes mellitus
should be assessed against the current background of inadequate
glycemic control, especially in patients with type 2 disease 
(AACE 2007). In particular what is the level of evidence for: 
• adequate glycemic control both short- and long-term
• prevention of acute episodes of hyperglycemia and
hypoglycemia
• tolerability, treatment tolerance, and impact on QOL
• longer-term reduction of microvascular and macrovascular
complications; improvement in QOL and survival.
The clinical efficacy of insulin glargine administered
subcutaneously once daily has been extensively investigated in
patients with type 1 and type 2 diabetes mellitus treated for
periods of up to 40 months. There is now available a wealth of
data from large well-controlled (randomized, multicenter, parallel-
group) clinical trials assessing the efficacy and tolerability of
insulin glargine. Most studies evaluated its utility in 
basal/bolus regimens and in many trials it was compared 
with NPH insulin, the most widely used replacement for basal
insulin. It should be noted that a drawback of a majority of these
studies is that they were of open-label design; mainly as a
consequence of the different appearance of the insulin
preparations (insulin glargine is presented as a clear solution and
NPH insulin as a turbid suspension). Clinical endpoints in the
majority of trials were indicators of glycemic control such as
fasting blood glucose (FBG), fasting plasma glucose (FPG),
glycosylated hemoglobin (HbA1c), and diurnal glucose response,
and tolerability (especially hypoglycemia). A growing number of
trials have taken a more holistic view and measured patient
satisfaction, wellbeing, QOL, and other factors impacting overall
health benefit (includingseveral economic analyses). The results
of pivotal clinical trials published to date are presented 
in Tables 3–7.
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Study Treatment Study
duration
Change from baseline to endpoint      Insulin dose Frequency of hypoglycemia 
(% patients)
FBG
(mmol/L)
FPG
(mmol/L) 
HbA1c
(%)
Symptomatic Nocturnal Severe
Studies in adults
Raskin et al.
2000
IG once daily (n=310)
NPH once or twice
daily (n=309)
16 weeks –1.7
–0.6
P=0.0001
–2.2
–0.7
P=0.0001
–0.1
–0.1
P=NS
–4.5 Ua; +1.5 Ub
+0.9 Ua; –0.5 Ub
P=NS
90.6
90.6
P=NS
69.0
63.1
P=NS
6.5
5.2
P=NS
Ratner et al.
2000
IG once daily (n=264)
NPH once or twice
daily (n=270)
28 weeks –1.12
–0.94
P=NS
–1.67
–0.33
P=0.01
–0.16
–0.21
P=NS
–5 Ua; +3.9 Ub
+1.8 Ua; +1.7 Ub
39.9
49.2
P<0.05
18.2
27.1
P<0.05
1.9
5.6
P=NS
Hershon et
al. 2004
IG once daily (n=195)
NPH twice daily
(n=199)
28 weeks –1.17
–0.56
P=0.02
ND
ND
–0.09
–0.19
P=NS
–7.1 Ua; +6.1 Ub
–2.3 Ua; +1.0 Ub
73.3
81.7
P=0.02
71.2
69.5
P=NS
2.6
5.1
P=NS
Home et al.
2005
IG once daily (n=292)
NPH once or twice
daily (n=293)
28 weeks –1.17
–0.89
P=NS
–0.82
–0.79
P=NS
0.21
0.10
P=NS
–2.0 Uc
0
P=NS
89.0
84.6
P=NS
61.0
61.1
P=NS
10.6
15.0
P=NS
Study in children
Schober et
al. 2002
IG once daily (n=174)
NPH once or twice
daily (n=175)
28 weeks –1.29
–0.68
P=0.02
ND
ND
0.28
0.27
P=NS
–1.3 Ua
+2.4 Ua
79.3
78.9
P=NS
48
52
P=NS
23.0
28.6
P=NS
aBasal dosage; bPreprandial dosage; cTotal insulin dosage.
FBG, fasting blood glucose; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; IG, insulin glargine; NPH, neutral protamine hagedorn; NS, nonsignificant; ND, no details provided.
Table 3 | Level 2 evidence of glycemic control in patients with type 1 diabetes mellitus treated with once-daily insulin glargine or 
once- or twice-daily NPH insulin as part of a basal/bolus regimen. All studies were open-label, randomized, multicenter,
and included >100 patients per treatment group93
Clinical evidence with insulin glargine in type 1 
diabetes mellitus
Patients with type 1 diabetes require replacement insulin for
survival and the current treatment regimen of choice is the
basal/bolus approach, whereby a basal insulin is administered to
provide 24-hour cover and supplementary rapid/short-acting
insulin analogs are given at meal times to mimic physiologic
prandial insulin release. The introduction of rapid-acting insulin
analogs, such as insulin aspart, insulin glulisine, and insulin lispro,
has greatly assisted the basal/bolus management approach and
this has increased the need for an improved basal insulin to
provide full 24-hour cover (Hamann et al. 2003). Conventional
longer-acting insulin preparations, such as NPH, have not
provided consistent 24-hour cover, thus necessitating twice-daily
administration in some individuals. NPH insulin also has an early
peak at around 4 to 6 hours following subcutaneous injection and
this can be associated with hypoglycemia, a limiting and
potentially dangerous adverse effect (Home et al. 2005). Insulin
glargine is a recently developed, long-acting basal insulin that has
been found to have a stable absorption rate without any
pronounced peaks in plasma concentration, thereby providing
near 24-hour cover (Heinemann et al. 2000; Lepore et al. 2000;
Owens et al. 2000; Scholtz et al. 2005) (Fig. 1).
In two of the earliest studies involving type 1 diabetes (n>500
patients) previously treated with basal/bolus regimens for at least
2 months, insulin glargine (containing 30 or 80 mg zinc)
administered once daily was more effective in lowering FPG levels
than NPH insulin (Pieber et al. 2000; Rosenstock et al. 2000).
However, these trials were of relatively short duration 
(4 weeks). 
Clinical evidence with insulin glargine in type 1 diabetes mellitus 
is based on large (>100 patients per treatment group), longer-
term (≥16 weeks), multicenter RCTs (four in adults, and one in
children), providing level 2 evidence (Table 3). These studies were
all open-label comparisons of once-daily insulin glargine with
either once- or twice-daily NPH insulin as part of a basal/bolus
regimen; the dose of basal insulin was titrated according to a
target FBG level. Only outcomes related to glycemic control
(including hypoglycemia) are discussed in this section; outcomes
pertaining to the tolerability and safety of insulin glargine will be
discussed separately.
Glycemic control in adults: insulin glargine versus NPH insulin
Raskin and colleagues (2000) compared the effects of insulin
glargine once a day at bedtime and NPH insulin once or twice a
day (for 16 weeks) as basal insulin treatment in patients with type
1 diabetes who were previously receiving NPH insulin for basal
treatment and preprandial insulin lispro for mealtime cover. They
concluded that basal insulin therapy with insulin glargine once a
day appears to be as safe and at least as effective as using NPH
insulin in maintaining glycemic control in patients receiving bolus
insulin lispro to cover postprandial glucose surges. Insulin
glargine was associated with significantly greater reductions in
both FBG and FPG than NPH insulin (P=0.0001). Furthermore,
more patients in the insulin glargine group achieved a target FBG
value of <6.7 mmol/L (29.6% vs 16.8% in NPH insulin group).
There was no difference between treatment groups with regards
the occurrence of hypoglycemia.
In a 28-week study, Ratner and colleagues (2000) found that
significant reductions in median FPG levels occurred with insulin
glargine compared with NPH insulin and that reductions in
capillary FBG levels, although comparable between the two
groups at the end of the study, occurred much earlier with insulin
glargine. At week 8, for example, mean FBG levels were reduced
by 1.17 mmol/L in the insulin glargine group versus only 
0.37 mmol/L in the NPH group (P<0.0001). Importantly, insulin
glargine was associated with fewer hypoglycemic episodes than
NPH insulin. As the majority of patients with type 1 diabetes use
NPH insulin twice daily, Hershon et al. (2004) conducted a
subgroup analysis using only data from patients treated with once-
daily insulin glargine and twice-daily NPH insulin. The findings of
this subgroup analysis support the results and conclusions from
the original study. The decrease in FBG level with insulin glargine
was significantly greater than with NPH insulin and, in addition, a
greater percentage of patients reached a target FBG level of <6.66
mmol/L (32.6% in insulin glargine group vs 21.3% in NPH insulin
group; P=0.02). Once again, insulin glargine was associated with
fewer episodes of symptomatic hypoglycemia.
Home and colleagues (2005) also found that once-daily insulin
glargine produces a level of glycemic control comparable to that
provided by once- or twice-daily NPH insulin, without an
increased risk of hypoglycemia. However, treatment satisfaction
and psychologic wellbeing were also evaluated in these patients
(Witthaus et al. 2001) and showed that insulin glargine 
has an advantage with respect to psychologic outcomes, as
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Fig. 1 | Diagramatic representation of the glycodynamic activity
profile of insulin glargine and NPH insulin (as determined
by GIR, based on results from euglycemic clamp studies)
after administration of 0.4 U/kg to healthy volunteers
(Heinemann et al. 2000) and 0.3 U/kg to patients with
type 1 diabetes (Lepore et al. 2000). GIR, glucose
infusion rate; NPH, neutral protamine hagedorn.Insulin glargine | clinical impact review
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people are apparently more satisfied with treatment with 
insulin glargine compared with NPH insulin. Improved patient
satisfaction was recently confirmed in a 36-week crossover 
trial (a 4-week run-in followed by 16 weeks of each active
treatment) comparing insulin glargine plus insulin aspart with NPH
insulin plus insulin aspart in 60 type 1 diabetic patients (Chaterjee
et al. 2007). 
A number of smaller, well-controlled trials have confirmed the
clinical benefits of insulin glargine. For example, Bolli and
colleagues (2006) treated type 1 diabetic patients for 6 months
with prandial insulin lispro plus either once-daily insulin glargine
(n=85) or twice-daily NPH insulin (n=90). Reductions in mean daily
FPG during the last month of treatment were significantly greater
with insulin glargine (–1.5 mmol/L) than NPH insulin (–0.5 mmol/L;
P<0.05). Furthermore, insulin glargine was associated with less
glucose variability as documented by reduced mean amplitude of
glycemic excursion (MAGE) values after 6 months’ treatment. In
125 patients with type 1 diabetes treated for >1 year and still
poorly controlled (HbA1c ≥8%), insulin glargine subcutaneously
once daily (n=62) was compared with NPH insulin once daily
(n=63) as basal insulin replacement in an intensive treatment
strategy (insulin lispro was given 3 times a day at mealtimes) over
a period of 30 weeks. Insulin glargine was superior to NPH insulin
with respect to improving HbA1c, lowering FBG levels, and causing
a lower incidence of moderate to severe nocturnal hypoglycemia
(Fulcher et al. 2005). Garg and colleagues (2005) compared
basal/bolus regimens involving insulin glargine/insulin glulisine
(premeal), insulin glargine/insulin glulisine (postmeal), and premeal
regular human insulin in 860 patients with type 1 diabetes 
treated for 12 weeks. The premeal glulisine regimen resulted 
in lower HbA1c levels and better postprandial glucose levels 
than those recorded for regular human insulin. The authors
concluded that bolus insulins, such as glulisine, have more
appropriate time–action profiles than regular human insulin and, in
combination with newer insulin analogs such as basal insulin
glargine, they may provide a more physiologic and convenient
basal/bolus regimen.
Subcutaneous insulin glargine administered once daily at
dinnertime has been compared with NPH insulin administered 
four times daily as part of intensive insulin regimens in studies of 
3 months’ (Rossetti et al. 2003) and 12 months’ (Porcellati et al.
2004) duration. Both trials noted advantages for insulin glargine
over NPH insulin in terms of lower daily blood glucose levels, the
proportion of patients achieving blood glucose target during the
day, reduction in HbA1c, a lower incidence of hypoglycemia, and
simpler dosage schedule. 
The reviewed studies provide a body of evidence highlighting the
efficacy (and tolerability in terms of hypoglycemia) of insulin
glargine administered subcutaneously once daily to patients with
type 1 diabetes mellitus. Overall, it has been shown to be at least
as effective as NPH insulin administered either once or twice daily
as part of a basal/bolus treatment strategy. Indeed, this evidence
was reviewed by the National Institute for Health and Clinical
Excellence (NICE 2002), which approved its use in patients with
type 1 diabetes.
Glycemic control in adults: insulin glargine versus other
antidiabetic treatments
Pieber and colleagues (2007) compared twice-daily insulin detemir
(n=161) and once-daily insulin glargine (n=159), both in
combination with bolus insulin aspart, in patients with type 1
diabetes. Glycemic control was similar for the two treatments with
the exceptions that insulin glargine produced a significantly lower
FPG level (7.0 vs 7.7 mmol/L; P<0.001) and insulin detemir a
significantly lower predinner plasma glucose concentration
(P<0.05). The overall risk of hypoglycemia was also comparable
for the two basal insulin therapies, although detemir was
associated with significantly fewer severe (73%) and nocturnal
(32%) episodes. Changes in bodyweight were not significantly
different between the two groups in this 26-week trial. Both basal
insulin dosage and total daily insulin dosage were higher in the
insulin detemir group (0.47/0.83 vs 0.35/0.74 U/kg, respectively).
Contrasting results come from an observational study recently
published by Currie and colleagues (2007). A total of 2808 patients
treated with insulin glargine and 333 patients treated with insulin
detemir were sourced from The Health Improvement Network
(THIN) database (UK general practices) and analyzed. The results
showed a trend favoring insulin glargine both in terms of glycemic
control and reduced hypoglycemia. 
The introduction of rapid-acting insulin analogs has aided the
development of intensified insulin regimens which are designed 
to maintain tight glycemic control, and thus reduce longer-term
complications associated with type 1 diabetes. This intensified
basal/bolus approach to diabetes management is best achieved
with either a continuous subcutaneous insulin infusion or multiple
daily administration of NPH insulin, augmented with a rapid-acting
insulin to provide mealtime cover (Rosetti et al. 2003). The
introduction of insulin glargine provides an alternative basal insulin
strategy given its 24-hour profile with no distinct peaks in activity,
and two recent small studies have compared basal therapy with
insulin glargine with that of continuous subcutaneous infusion in
patients with type 1 diabetes.
In a crossover trial of short duration (5 weeks per treatment)
continuous subcutaneous insulin aspart infusion resulted in lower
glycemic exposure without an increased risk of hypoglycemia, as
compared with multiple daily injections of insulin aspart/insulin
glargine (Hirsch et al. 2005). The authors noted that for patients
receiving continuous infusion therapy, multiple injections with
insulin aspart/insulin glargine is a viable option for periods when
the pump cannot be used (for example because of a pump
malfunction, skin problems, physical activity, etc). A similar
conclusion was reached by Bode and colleagues (2005) in a study
involving 38 patients with type 1 diabetes who switched from
continuous subcutaneous infusion with insulin lispro to multiple
daily injections with insulin glargine and insulin lispro. In this trial,
insulin glargine was administered at a dosage equal to (1:1) or 1.2
times (1:1.2) the mean total daily continuous subcutaneous
infusion basal insulin dose, and the former (1:1) was
recommended as the preferred choice for pump-free periods since
it provided effective glycemic control and a lower propensity for
causing hypoglycemia.95
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Studies assessing insulin glargine administration regimens
A number of studies have assessed issues relating to timing of
administration, titration, and dosage. The AT.LANTUS Study Group
reported that in a large population of patients with long-standing,
suboptimally controlled, type 1 diabetes (n=2442), two insulin
glargine regimens (insulin glargine increased in increments of at
least 10%, but not >4 U; or insulin glargine increased in increments
of 1–6 U) produced equivalent statistically significant improvements
in glycemic control with low rates of severe hypoglycemia (Gomis
et al. 2007). In terms of timing of administration, Hamann et al.
(2003) reported no clinically relevant differences in efficacy or safety
with insulin glargine administered before breakfast, before dinner,
or at bedtime. Likewise, Grimaldi and colleagues (2007) observed
no clinically relevant differences in efficacy or tolerability in type 1
diabetic patients administered insulin glargine at dinnertime
(n=589) or bedtime (n=589) for 26 weeks.
Some clinicians have observed predinner increases in blood
glucose levels when insulin glargine is injected at bedtime, and
Ashwell and colleagues (2006a) have suggested that it may be
better to administer insulin glargine at lunchtime or dinnertime to
avoid this effect. The same group (Ashwell et al. 2006b) assessed
once (dinnertime) and twice (half doses administered at breakfast
and dinnertime) daily administration of insulin glargine in a
crossover study involving 20 patients with type 1 diabetes treated
for 4 weeks. The twice-daily regimen resulted in lower blood
glucose levels after breakfast, lunch, and before dinner, and it was
also associated with lower mean 24-hour blood glucose levels 
(7.1 vs 8.8 mmol/L; P=0.031) and less within-day variability in blood
glucose levels (P=0.044). The authors concluded that for patients
who experience late afternoon increases in blood glucose levels,
twice-daily insulin glargine is a suitable alternative which does not
require an increase in insulin dosage nor does it negatively impact
treatment satisfaction.
Glycemic control in children
The principle of achieving tight metabolic control in patients with
type 1 diabetes so as to delay the onset and slow the progression
of both microvascular and macrovascular complications applies
as much to children as it does to adults (DCCT Research Group
1994). However, adequate control is difficult in younger patients
due to endocrine, behavioral, and social factors. As a result, less
than one-third of children and adolescents being treated for
diabetes are considered to be well controlled (Mortensen &
Hougaard 1997).
Schober and colleagues (2002) compared the efficacy of insulin
glargine with NPH insulin in children and adolescents aged 
5–16 years with type 1 diabetes mellitus. Although there was no
difference between the insulin glargine and NPH insulin treatment
groups with respect to baseline-to-endpoint change in HbA1c
levels, significant reductions in FBG levels were observed with
insulin glargine (–1.29 mmol/L) compared with NPH insulin 
(–0.68 mmol/L; P=0.02). In addition, a higher percentage of
patients using insulin glargine (43.9%) reached the target FBG
level at endpoint compared with NPH insulin (39.0%). The
frequency of symptomatic hypoglycemia was similar between the
two groups despite a nonsignificant trend to fewer episodes of
severe hypoglycemia and severe nocturnal hypoglycemia in those
treated with insulin glargine.
These findings are supported by a recent smaller study by Chase
et al. (2006), who compared the efficacy of once-daily insulin
glargine (n=85) with twice-daily NPH or lente (n=90) as basal
therapy in pediatric patients with type 1 diabetes treated with a
multiple daily injection regimen including premeal insulin lispro.
Despite only a small reduction in mean HbA1c from baseline to
endpoint in both groups, they reported that in patients with a high
baseline HbA1c, insulin glargine produced a significantly greater
reduction in mean HbA1c than NPH/lente. Patients treated with
insulin glargine also showed less blood glucose variability
assessed during continuous blood glucose monitoring. Rates 
of hypoglycemia were comparable between the two 
treatment groups.
A retrospective analysis of the medical records of 64 children with
type 1 diabetes aged under 6 years documented a decrease in
severe hypoglycemia, particularly at night, during the first 
6 months of therapy with insulin glargine (Dixon et al. 2005). In the
6 months before the study period, 16 severe hypoglycemic events
were observed compared with three during the first 6 months of
insulin glargine therapy (12 night-time severe hypoglycemic events
were noted prestudy and only one during treatment with insulin
glargine). Similar results were recorded in a group of 34 preschool
children (aged 2.6–6.3 years) who were treated with a flexible
multiple-day insulin regimen (premeal lispro plus bedtime glargine)
for at least 1 year (Alemzadeh et al. 2005). HbA1c and the incidence
of severe hypoglycemia were significantly reduced compared with
previous treatment (premeal lispro plus twice-daily ultralente) and
the best results were achieved in children with normal bodyweight.
Given the adverse impact severe hypoglycemia may have on the
developing brain in young children, the authors recommend that
further controlled studies should be undertaken to confirm these
clinically important findings.
Another retrospective case analysis assessed the effectiveness of
insulin glargine in patients under 21 years (range 2–20 years) with
considerably higher mean HbA1c levels at baseline (9.7±1.9%)
despite previously receiving NPH insulin (Hathout et al. 2003). The
majority of patients had type 1 diabetes and HbA1c was
significantly decreased from a baseline of 9.5% to 8.6% (P<0.001)
following 9 months’ treatment with insulin glargine. This reduction
was associated with a significant decrease in hypoglycemia
(12.2% to 10.7%; P=0.004), but surprisingly little change in mean
blood glucose levels. Colino et al. (2005) also documented a
significant reduction in HbA1c levels following 6 months’ therapy in
80 patients aged 2 to 19 years with type 1 diabetes treated with
insulin glargine plus short-acting (regular human) insulin or a rapid-
acting analog to provide mealtime cover. HbA1c fell from 7.63% 
to 7.14% (P<0.001) in the total cohort and this reduction 
was associated with decreased FBG (161 to 150 mg/dL; P=0.05)
and a lower incidence of severe hypoglycemia (0.18 to 0.11
events/patient; not significant). In a study of shorter duration 
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(P<0.05) greater reduction in HbA1c levels following continuous
subcutaneous insulin infusion (8.1% to 7.2%) compared 
with a multiple daily injection regimen including insulin
glargine (8.2% to 8.1%) in 32 young patients (8–21 years) with
type 1 diabetes treated for 16 weeks. However, in a similarly
designed study involving 32 type 1 diabetic children (mean 
age 12.5 years) treated for 2 years with continuous
subcutaneous insulin infusion or a multiple daily injection
regimen including insulin glargine, the two treatment approaches
were found to be equally effective and well tolerated (Garcia-
Garcia et al. 2007).
Insulin dosage
In all five of the studies summarized in Table 3, the daily basal
insulin dose tended to increase from baseline to endpoint for
those patients in the NPH insulin treatment group. In
comparison, there was a decrease in those receiving insulin
glargine and this was almost entirely due to a reduction in the
daily basal insulin dose seen in those patients previously using a
twice-daily NPH insulin regimen. This fall in daily basal insulin
dose was associated with a small increase in total daily bolus
dosage (short- or rapid-acting insulins). It has been suggested
that this need for less basal insulin when using insulin glargine,
along with the lower FBG levels it results in, may allow for more
aggressive bolus therapy with fast-acting insulins, and this may
further help improve glycemic control in patients with type 1
diabetes (Hershon et al. 2004).
Clinical evidence with insulin glargine in adults with type 2
diabetes mellitus
Insulin therapy in patients with type 2 diabetes mellitus is
generally reserved for patients unresponsive to management
with diet, exercise, and oral antidiabetic drugs. This is reflected
in clinical trials involving insulin glargine since inclusion criteria
usually specified patients with type 2 diabetes who did not
achieve good metabolic control (usually HbA1c >7–7.5%) despite
being treated with one or more oral antidiabetic agents. Clinical
assessment of insulin glargine in patients with type 2 diabetes
has included the following:
• Large RCTs (level 2 evidence) and a meta analysis (level 1
evidence) versus NPH insulin
• Seven RCTs against premixed biphasic insulins (level 2
evidence)
• Two randomized clinical trials with exenatide (level 2
evidence)
• Randomized clinical trials versus rosiglitazone (n=4) and
pioglitazone (n=1) (both level 2 evidence)
• A large observational study from everyday practice in
Germany involving >12 000 patients (level 4 evidence)
• Two large randomized controlled “treatment approach” clinical
trials (level 2 evidence) assessing different treatment
algorithms.
Glycemic control in adults: insulin glargine versus NPH insulin
The emphasis in this section of the review is given to
randomized, controlled clinical trials which compared insulin
glargine with NPH insulin and included >200 patients with type 2
diabetes per treatment group (Table 4). All studies included
insulin-naïve patients except the studies of Rosenstock et al.
(2001) and Massi Benedetti et al. (2003); the latter is a follow-up
of the study reported by Yki-Järvinen et al. (2000), but includes
data from an additional 144 patients who had previously received
insulin therapy.
The results from six of these large controlled trials (level 2
evidence) comparing subcutaneous insulin glargine with
subcutaneous NPH insulin show that over a period of up to 
1 year, both insulin glargine and NPH insulin produced clinically
significant improvements in glycemic control with some trials
reporting high response rates. For example Riddle and
colleagues (2003) noted that the majority of patients (~60%)
attained an HbA1c level of 7% or less with both insulin glargine
and NPH insulin. Similarly Eliaschewitz et al. (2006) reported that
approximately 50% of patients achieved an HbA1c level of
<7.5%. Pan and colleagues (2007) observed a lower overall
response rate in terms of HbA1c (<7.5%) in Asian patients treated
with insulin glargine (38.1%) or NPH insulin (30.3%). However, a
greater percentage of patients (62.3% and 58.7%, respectively)
achieved a target FBG level of ≤120 mg/dL.
Interestingly, Fritsche et al. (2003) found that insulin glargine and
NPH insulin administered at bedtime reduced HbA1c to below
7.5% in approximately one-third of patients, but a significantly
greater number of patients responded when insulin glargine was
administered before breakfast (43%). In this study HbA1c levels
improved by a statistically greater extent with morning insulin
glargine (–1.24) than with either NPH insulin (–0.84; P<0.001) or
bedtime insulin glargine (–0.96; P=0.008). Insulin glargine
administered before breakfast resulted in a greater decrease in
mean daily blood glucose levels (determined during diurnal
blood glucose testing) compared with both bedtime NPH
(P<0.001) and bedtime insulin glargine (P=0.002). Yki-Järvinen et
al. (2000) reported a significantly greater decrease in blood
glucose concentrations before and after dinner in patients
treated with insulin glargine compared with those treated with
NPH insulin (both drugs administered at bedtime). Similarly, Pan
et al. (2007) observed lower glucose levels postdinner in the
insulin glargine group (236 vs 249 mg/dL; P<0.05), and also a
decrease in mean daily blood glucose levels (–94 vs –80 mg/dL;
P=0.018).
A consistent and important clinical finding in all of these large
trials was that insulin glargine resulted in a lower incidence of
nocturnal hypoglycemia than that associated with NPH insulin.
The authors of all these large randomized clinical trials
concluded that, compared with NPH insulin, once-daily insulin
glargine produced equivalent glycemic control (in two studies
there were some significant changes favoring insulin glargine),
but the newer insulin analog had the significant clinical
advantage of causing less nocturnal hypoglycemia—a frequent97
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barrier to starting insulin therapy in patients with type 2 
diabetes mellitus.
These findings have been augmented by a meta analysis (level 1
evidence) of four of these trials (Yki-Järvinen et al. 2000/Massi
Benedetti et al. 2003; Rosenstock et al. 2001; Fritsche et al 2003;
Riddle et al. 2003) which is summarized in Table 5 (Rosenstock 
et al. 2005). In this analysis, involving >1000 patients per 
treatment group, insulin glargine and NPH insulin produced
equivalent glycemic control as determined by the number of
patients achieving HbA1c levels ≤7.0%, although insulin 
glargine was associated with significantly lower FPG levels (8 vs 
9 mmol/L; P=0.023). In line with the conclusions reached by the
individual clinical trials, the main finding of clinical consequence
from the meta analysis was the significantly lower risk of
hypoglycemia occurring with insulin glargine. The risk reduction
was 59% for severe nocturnal hypoglycemia (P=0.0231), 
46% for severe hypoglycemia (P=0.0442), 26% for nocturnal
hypoglycemia (P<0.0001), and 11% for overall documented
hypoglycemia (P=0.0006).
Studies involving smaller numbers of patients have produced
comparable results to the large studies described above (HOE
901/2004 Study Investigators Group 2003; Fonseca et al. 2004;
Yki-Järvinen et al. 2006). Furthermore, at a titration target of 
FBG ≤5.5 mmol/L, Standl et al. (2006) noted that bedtime and
morning regimens of insulin glargine were equivalent in terms of
achieving good glycemic control without any significant difference
in hypoglycemia. In the longest study to date (an extension of the
large study reported by Yki-Järvinen et al. 2000 and Massi
Benedetti et al. 2003), 198 type 2 diabetic patients received
subcutaneous insulin glargine for up to a further 28 months in an
open noncontrolled clinical study. The longer-term efficacy
(assessed by HbA1c levels) and safety of insulin glargine was
confirmed in this trial (Kacerovsky-Bielesz et al. 2006). 
An interesting study reported by Gerstein and coworkers (2006) is
the Canadian Insight (Implementing New Strategies with Insulin
Glargine for Hyperglycemia Treatment) Study. This trial assessed
the “early” introduction of insulin glargine in 405 patients with
type 2 diabetes with an HbA1c of ≥7.5%, but not receiving full
Study Treatment Study
duration
Change from baseline to endpoint           Insulin dose Frequency of hypoglycemia (% patients)
FBG
(mmol/L)
FPG
(mmol/L) 
HbA1c (%) Symptomatic Nocturnal Severe
Riddle et al.
2003
IG o.n. (n=367)
NPH o.n. (n=389)
24 weeks ND
ND
–4.5
–4.1
P=NS
–1.65
–1.59
P=NS
47.2 U
41.8 U
P=0.005
13.9a
17.7a
P<0.02
4.0a
6.9a
P<0.001
2.5
1.8
P=NS
Rosenstock
et al. 2001
IG o.n. (n=259)
NPH o.n., or o.n. 
and o.m. (n=259)
28 weeks –1.3b
–1.2b
P=NS
ND
ND
–0.41
–0.59
P=NS
0.75 U/kgc
0.75 U/kgc
P=NS
61.4
66.8
P<0.05
31.3
40.2
P<0.02
ND
ND
Eliaschewitz
et al. 2006
IG once daily (n=231)
NPH once daily
(n=250)
24 weeks –4.8
–4.1
P=NS
ND
ND
–1.38
–1.44
P=NS
32.6 U
31.2 U
P=NS
52.8
62.8
P=0.042
20.4
34.8
P<0.001
2.6
4.4
P=0.303
Fritsche et al.
2003
IG o.m. (n=236)
IG o.n. (n=227)
NPH o.n. (n=293)
28 weeks –5.1
–5.2
–5.3
P=NS
ND
ND
ND
–1.24d
–0.96
–0.84
40 U
37 U
39 U
P=NS
56
43e
58
17f
23f
38
P<0.001
2.1
1.8
2.6
P>0.2
Yki-Järvinen
et al. 2000
IG o.n. (n=214)
NPH o.n. (n=208)
52 weeks NDg
NDg
ND
ND
–0.76
–0.66
P=NS
23 U
21 U
33b
42b
P=0.04
9.9
24
P<0.001
0
0
P=NS
Massi
Benedetti et
al. 2003
IG o.n. (n=289)
NPH o.n. (n=281)
52 weeks –2.7
–2.6
P=0.26
–2.8
–2.7
P=0.65
–0.46
–0.38
P=0.415
ND
ND
32.5
37.3
P=NS
9.5
22.2
P=0.0006
1.7
1.1
P=NS
Pan et al.
2007
IG o.n. (n=220)
NPH o.n. (n=223)
24 weeks –5.8
–5.7
P=NS
ND
ND
–0.99
–0.77
P=0.032
22 U
23 U
P=NS
515h
908h
P=0.0003
221h
620h
P=0.001
5h
28h
P<0.03
aEvents per patient-year; bEstimated from a graphical presentation; cTotal insulin dosage, basal + bolus; dP<0.001 vs NPH insulin and P=0.008 vs IG at bedtime; eP=0.001 vs NPH insulin 
and P=0.004 vs IG in the morning; fP<0.001 vs NPH insulin; gGlycemic control was equivalent for the two groups; hNumber of episodes of hypoglycemia. 
FBG, fasting blood glucose; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; IG, insulin glargine; NPH, neutral protamine hagedorn; ND, no details provided; NS, nonsignificant;
o.m., in the morning; o.n., at night (bedtime).
Table 4 | Level 2 evidence of glycemic control in patients with type 2 diabetes mellitus treated with once-daily insulin glargine or
once- or twice-daily NPH insulin in combination with oral antidiabetic drugs (except for Rosenstock et al. 2001, in which
regular human insulin premeals was maintained). All studies were randomized, multicenter, of open-label design, and
included >200 patients per treatment groupdoses of oral antidiabetic therapy. Two hundred and six patients
were randomized to receive insulin glargine and 199 to continue
usual dose titration with oral therapy (to a FPG of ≤5.5 mmol/L
and an HbA1c of ≤7%) for a period of at least 6 months.
Compared with usual therapy, patients receiving insulin glargine
achieved significantly better glycemic control as evidenced by
greater decreases in HbA1c (–1.55 vs –1.25%; P=0.005) and FPG
(–3.89 vs –2.31 mmol/L; P=0.0001), and the frequency of
achieving two consecutive HbA1c measurements ≤6.5% (insulin
glargine patients were 1.7 times more likely to reach this primary
endpoint; P=0.049). Insulin glargine therapy was also associated
with an improved lipid profile [decreased non-high-density
lipoprotein cholesterol (P=0.02) and triglycerides (P=0.02)] and
greater increases in treatment satisfaction (P=0.045), but
increased bodyweight (+1.9 kg; P<0.0001).
The above findings from well-controlled clinical trials have
recently been augmented by a 20-month observational study
(level 4 evidence) involving >12 000 type 2 diabetic patients
poorly controlled by oral therapy from everyday practice in
Germany (Schreiber & Haak 2007). The mean HbA1c level was
8.7% at baseline (n=11 511), and following the addition of insulin
glargine 7.2% at 3 months (n=11 296), 7.0% at 9 months
(n=6031), and 7.0% at 20 months (n=2374).
In the above studies, changes in bodyweight were generally
similar for insulin glargine and NPH insulin with two studies
reporting an advantage for glargine (Rosenstock et al. 2001;
Fonseca et al. 2004) but others noting nonsignificant reductions
with NPH insulin (Fritsche et al. 2003; Riddle et al. 2003). In the
large observational study reported by Schreiber and Haak (2007)
body mass index decreased slightly from a mean of 29.0 kg/m2
at baseline to 28.5 kg/m2 after 9 months of insulin glargine
treatment. 
Glycemic control in adults: insulin glargine versus other
antidiabetic treatments
Studies comparing once-daily insulin glargine with premixed
biphasic insulins in patients with type 2 diabetes mellitus poorly
controlled with oral antidiabetic drugs (and in one study plus
insulin; Malone et al. 2005) generally reported improved
metabolic control with all of the insulin regimens (Table 6). In
terms of which regimen is best with respect to improving
glycemic control the results have varied, but there is a trend
toward better glycemic control, increased insulin dosage, and an
increased incidence of hypoglycemia with the biphasic
preparations, but this has not been the case in all studies.
For example, Janka et al. (2005) found that once-daily (morning)
insulin glargine in combination with glimepiride and metformin
reduced FBG and HbA1c levels, and was associated with
significantly lower incidence of hypoglycemia compared with
human insulin (30% regular, 70% NPH) alone. Furthermore, these
advantages were also apparent in a subgroup of 130 patients
aged ≥65 years (Janka et al. 2007). In contrast, in the INITIATE
study, biphasic insulin aspart 30/70 in combination with oral
antidiabetic drugs produced a significantly greater reduction in
HbA1c levels than insulin glargine once daily (at bedtime) plus
oral antidiabetic drugs, but this was associated with a
significantly greater increase in biphasic insulin dosage (P<0.05),
weight gain (P<0.01), and incidence of minor hypoglycemia
(P<0.05) (Raskin et al. 2005). Similar findings were noted in a
subpopulation of patients who were not receiving
thiazolidinedione treatment in the original study (Raskin et al.
2007). Comparable results with biphasic insulin aspart 30/70
(plus metformin; n=128) versus insulin glargine (plus glimepiride;
n=127) were reported by Kann and colleagues (2006) in a
randomized trial in which patients were treated for 26 weeks.
Biphasic insulin aspart 30/70 resulted in a lower mean plasma
prandial glucose increment (calculated from a 7-point plasma
glucose profile), but increased minor hypoglycemia.
In two crossover trials involving relatively small numbers of
patients with type 2 diabetes poorly controlled by oral
antidiabetic drugs (Malone et al. 2004) or by intermediate insulin
with or without oral antidiabetic drugs (Malone et al. 2005), daily
insulin glargine (at bedtime) was compared with biphasic insulin
lispro 25/75. The authors concluded that biphasic insulin lispro
25/75 was a more effective treatment option because it resulted
in a greater decrease in HbA1c levels, a higher number of HbA1c
≤7% responders, and more patients achieving morning and
evening blood glucose targets. However, it should be noted that
insulin glargine produced a significantly greater decrease in FBG
levels, and more FBG ≤7 mmol/L responders. Insulin dosage was
not increased as much in the insulin glargine group (significantly
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Outcome measure Insulin  NPH insulin P value
glargine (n=1162)
(n=1142)
Patients with HbA1c ≤7.0% (% patients)
At baseline 3.1 3.3 P=NS
At endpoint 30.8 32.1 P=NS
Fasting plasma glucose (mmol/L)
At baseline 11 11 P=NS
At endpoint 8 9 P=0.023
Basal insulin dosage (U)
At baseline 21 21 P=NS
At endpoint 38 37 P=NS
Symptomatic hypoglycemia (% patients)
Overall documented 54.2 61.2 P=0.0006
Nocturnal documented 28.4 38.2 P<0.0001
Nonnocturnal documented 49.6 51.7 P=0.4642
Severe documented 1.4 2.6 P=0.0442
Severe nocturnal documented 0.7 1.7 P=0.0231
Severe nonnocturnal documented 0.8 0.9 P=0.7296
Table 5 | Meta analysis of four randomized, open-label, 
clinical trials comparing insulin glargine (n=1142) 
with NPH insulin (n=1162) in patients with type 2
diabetes poorly controlled by oral antidiabetic drugs 
[or receiving preprandial regular human insulin
(Rosenstock et al. 2001)] (Rosenstock et al. 2005)
HbA1c, glycosylated hemoglobin; NPH, neutral protamine hagedorn; NS, nonsignificant.99
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so in the most recent study; Malone et al. 2005). Changes with
respect to hypoglycemia favored insulin glargine in one study
(Malone et al. 2004) and biphasic insulin lispro in the other
(Malone et al. 2005). The same group recently reported results
from a crossover trial involving 20 patients with type 2 diabetes
inadequately controlled by metformin and/or a sulfonylurea 
who received additional treatment with biphasic insulin 
lispro 25/75 or insulin glargine (Roach & Malone 2006). 
After 3 months’ treatment, 24-hour test meal assessments
demonstrated that biphasic insulin lispro 25/75 was 
associated with lower mean postprandial glucose and 
24-hour plasma glucose, but similar FPG. It was also associated
with an increase in mild hypoglycemia. Intensive treatment 
with biphasic insulin lispro (injecting lispro 50/50 before 
breakfast and lunch, and lispro 25/75 before dinner) produced
better overall glycemic control (HbA1c and postprandial 
blood glucose levels) than insulin glargine, but it was associated
with an increased incidence of mild hypoglycemia (Jacober et 
al. 2006).
Recent comparative studies in patients with poorly controlled 
type 2 diabetes demonstrated the following results with once-
daily insulin glargine:
• Insulin glargine was as effective as twice-daily exenatide 
5–10 mcg twice daily, and was associated with a significantly
lower incidence of gastrointestinal side effects (Heine et al.
2005; Secnik Boye et al. 2006). In the latter study insulin
glargine and exenatide demonstrated comparable
improvements in treatment satisfaction.
• In four clinical trials insulin glargine and rosiglitazone produced
similar levels of glycemic control in double- or triple-therapy
regimens (Rosenstock et al. 2006; Triplitt et al. 2006; Reynolds
et al. 2007; Vinik & Zhang 2007). Rosenstock and colleagues
(2006) reported greater reductions in HbA1c levels in patients
whose baseline value was ≥9.5%, while Vinik and Zhang
(2007) noted statistically significant improvements in QOL
measures for insulin glargine compared with rosiglitazone.
• Insulin glargine improved glycemic control and diabetes-
related QOL compared with pioglitazone (Meneghini et al.
2006).
• In older patients (≥60 years) with poorly controlled type 2
diabetes, intensive therapy with continuous subcutaneous
infusion or multiple daily injections (insulin lispro/insulin
glargine) resulted in an HbA1c <7% response rate of
approximately 80% (Herman et al. 2005).
Reference Treatment Change from baseline            Insulin dose Hypoglycemia Pts achieving
blood glucose
target of
<5.6–7.0
mmol/L (%)
Pts
achieving
HbA1c level
<7% FBG
(mmol/L)
HbA1c
(%)
Symptomatic
(% pts)
Nocturnal 
(% pts)
Janka et al.
2005
IG once dailya (n=177)
Premixed human insulin 30/70
twice dailyb (n=187)
–3.1
–2.2
P=0.0001
–1.64
–1.31
P=0.0003
+18.3 U
+43.9 U
2.62c
5.73c
P=0.0009
0.51c
1.04c
P=0.045
31.6
15.0
P=0002
49.4
31.0
P=0.06
Raskin et al.
2005
IG once dailyd (n=116) 
Biphasic insulin aspart 30/70
twice daily (n=117)
125e
125e
P=NS
–2.36
–2.79
P<0.01
+0.42 U/kg
+0.68 U/kg
P<0.05
0.7f
3.4f
P<0.05
ND
ND
57g
36g
40
66
P<0.001
Kann et al.
2006
IG once daily (n=127) +
glimepiride
Biphasic insulin aspart 30/70
twice daily (n=128) + metformin
–2.2h
–2.6h
P=0.23
–0.2
–0.5
P=0.0002
ND
ND
9.0
20.3
P=0.012
ND
ND
ND
ND
26.2
33.1
P=0.27
Malone et
al. 2004
IG once dailyi (n=53)
Biphasic insulin lispro 25/75
twice dailyj (n=52)
–1.61
–0.75
P<0.001
–0.9
–1.3
P=0.003
+0.18 U/kg
+0.23 U/kg
P=0.001
0.39k
0.68k
P=0.041
12
11
P=NS
65
45
P=0.019
18
42
P<0.001
Malone et
al. 2005
IG once dailyi (n=47) 
Biphasic insulin lispro 25/75
twice dailyj (n=50)
–1.03
–0.52
P=0.007
–0.42
–1.00
P<0.001
+0.09 U/kg
+0.15 U/kg
P<0.001
0.44
0.61
P=0.477
0.34
0.14
P<0.002
51
34
P=0.01
12
30
P=0.002
Jacober et
al. 2006
IG once dailyd (n=60)
Biphasic insulin lispro 50/50
before breakfast and lunch
and biphasic insulin lispro
25/75 before dinner (n=60)l
ND
ND
–0.75
–1.01
P=0.008
2.57
3.98
P=0.001
0.80
1.05
P=0.36
ND
ND
31
44
P=0.103
aIn the morning in combination with glimepiride and metformin; bWithout oral antidiabetic drugs; cMean number of events/patient per year; dAt bedtime in combination with oral antidiabetic drugs;
eDecrease in FPG in mg/dL; fIncidence of minor hypoglycemic events/patient per year; gPatients achieving a target FPG of 80–110 mg/dL; hFPG; iAt bedtime in combination with metformin; 
jIn combination with metformin; kOverall rate of hypoglycemia (events/patient/30 days); lCrossover study.
FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; IG, insulin glargine; ND, no details provided; NS, nonsignificant; pts, patients.
Table 6 | Level 2 evidence of glycemic control in patients with type 2 diabetes mellitus poorly controlled on previous therapy,
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• Insulin glargine and prandial insulin lispro produced similar
reductions in HbA1c levels, but insulin glargine was 
associated with significantly lower FBG levels, nocturnal blood
glucose, and a lower incidence of hypoglycemia (as well as
fewer injections and less self-monitoring of blood glucose
levels), whereas insulin lispro produced better control of
postprandial blood glucose levels (Bretzel et al. 2006).
• Based on findings from an observational analysis using 
data from UK general practices, insulin glargine (n=2875)
tended to produce slightly improved diabetes control than
insulin detemir (n=361) and less hypoglycemia (Currie et 
al. 2007).
Glycemic control in adults: “treatment approach”
In a large clinical trial, Davies et al. (2005) compared two
treatment approaches with insulin glargine in >4000 patients
with type 2 diabetes. As in most other clinical trials insulin
dosage was titrated to specific FBG targets and the aim of 
this trial was to compare investigator/physician-led titration with
patient self-managed titration over a 24-week period.
Interestingly, the self-managed approach to insulin glargine
dose titration resulted in higher dosages of insulin being
administered and this was associated with better glycemic
control (as measured by HbA1c and FBG levels) and an increase
in symptomatic hypoglycemia (but not severe or nocturnal
episodes).
More recently, Kennedy et al. (2006) assessed glycemic control
using a combination of active versus usual algorithmic titration
approaches, and point-of-care versus laboratory measurement of
HbA1c. This trial included >7500 patients with type 2 diabetes
treated for a period of 24 weeks; the best results in terms 
of lowering of FBG (self-monitored) and proportion of patients with
HbA1c levels <7% was achieved with active titration and 
point-of-care monitoring. Active titration was defined as weekly
patient contact (telephone, fax, email) to review general wellbeing,
review glucose values, and reinforce insulin titration; this was in
addition to the usual titration that occurred every 6 weeks. 
Quality of life
Diabetes mellitus is a chronic, often debilitating disease which
can affect many aspects of day-to-day life. In its most severe
forms, when poorly controlled, the disease is associated with
longer-term microvascular (retinopathy, neuropathy, and
nephropathy) and macrovascular complications. Treatment
should be multifactorial so as to achieve optimal control of the
underlying disease, and to alleviate symptoms and minimize risk
of long-term complications. This in itself may impact the patient’s
wellbeing, but it is further confounded by the side effects of
intensive glycemic treatment such as potentially disabling
hypoglycemia, weight gain, and increased cost to 
the patient.
In clinical trials a number of authors commented on the positive
impact of insulin glargine on patient wellbeing and its
acceptance by patients (Schober et al. 2002; Doyle et al. 2004;
Colino et al. 2005; Herman et al. 2005; Home et al. 2005; Bretzel
et al. 2006; Eliaschewitz et al. 2006; Meneghini et al. 2006;
Chaterjee et al. 2007). As part of a formal analysis of treatment
satisfaction and physiologic wellbeing, Witthaus et al. (2001)
assessed 517 patients with type 1 diabetes participating in an
RCT in Europe using the Diabetes Treatment Satisfaction
Questionnaire (DTSQ) and the Well-Being Questionnaire (W-BQ).
After 28 weeks’ therapy, insulin glargine produced an
improvement in “treatment satisfaction” which was significantly
superior to that produced by NPH insulin (difference between
treatments was 1.83 points; P<0.001). Both insulin preparations
decreased “perceived frequency of hyperglycemia” scores but
the effect was significantly more pronounced with insulin glargine
(P=0.037). Psychologic wellbeing scores were improved equally
by insulin glargine and NPH insulin. These findings were
augmented by those of Manini et al. (2007) who reported
significant improvements in Well-being Enquiry for Diabetics
(WED) related to discomfort (P=0.02), impact (P=0.0002), and
total score (P=0.0005) in 40 type 1 diabetic patients switched
from NPH insulin to insulin glargine because of suboptimal
control. The health-related quality of life (HRQL)-WED
questionnaire was undertaken at 6–8 months after switching to
insulin glargine, at which stage there was a perceived lower risk
of hypoglycemia and less problems in daily life with insulin
glargine and, importantly, HbA1c was reduced by 0.7%
(P<0.0001 vs baseline).
Similarly, in a general practice study involving 135 patients with
type 1 diabetes and 180 patients with type 2 diabetes, insulin
glargine produced significant improvements in HRQL in a subset
of 50 patients who completed the survey (Fischer et al. 2004).
Statistically significant improvement was recorded for scores
relating to total symptoms (34.8%; P<0.0001), total symptom
distress (42.6%; P<0.0001), overall wellbeing (P=0.002), 
and emotional wellbeing (P=0.003) compared with baseline
values. These improvements in QOL were associated with
significantly improved glycemic control as assessed by HbA1c
levels (reduced by 0.28±1.47, P=0.03, in type 1 diabetic patients;
and reduced by 0.6±1.51, P<0.0001, in type 2 
diabetic patients).
Meneghini and coworkers (2006) assessed HRQOL in 230 
type 2 diabetic patients treated with insulin glargine (n=112) or
pioglitazone (n=118), as add-on therapy, over a period of 
48 weeks. Insulin glargine produced greater improvement in 
17 of 20 HRQL measures from baseline to week 48 compared
with pioglitazone. The results were statistically significant
(P<0.05) for domains measuring psychologic distress related to
hyperglycemic symptoms, fatigue, and total symptom-related
distress. Using multivariate analysis insulin glargine was
associated with significantly better outcomes for hyperglycemic
and ophthalmologic symptoms, and for psychologic distress
related to fatigue, hyperglycemic, hypoglycemic, ophthalmologic,
and cardiovascular symptoms. Similar findings were recently
reported by Vinik and Zhang (2007) in a randomized, multicenter
study comparing insulin glargine and rosiglitazone as add-on
therapy in 217 patients with poorly controlled type 2 diabetes101
despite being treated with a sulfonylurea plus metformin. The two
drugs were equally effective in terms of improving glycemic
control, but insulin glargine produced significantly greater benefits
over rosiglitazone in the Diabetes Symptom Checklist-Revised
(DSC-R) total symptom score (P=0.005), total distress score
(P=0.03), and individual domain scores for mood symptoms
(P=0.007), ophthalmologic symptoms (P=0.007), ophthalmologic
distress (P=0.013), fatigue distress (P=0.033), and Short Form-36
(SF-36) perception of general health (P=0.047). Finally, in a
randomized, multicenter, 26-week clinical trial once-daily insulin
glargine (n=227) and twice-daily exenatide (n=228) were found to
be equally efficacious in terms of glycemic control and improving
QOL as assessed by DSC-R, DTSQ, and the SF-36 vitality
subscale (Secnik Boye et al. 2006).
Tolerability and safety of insulin glargine
According to the Physicians’ Desk Reference (PDR) the 
adverse reactions most commonly associated with insulin
glargine include:
• body as a whole—allergic reaction
• skin and appendages—injection site reaction, lipodystrophy,
pruritus, rash
• other—hypoglycemia.
In one of the largest studies published to date, 7893 patients
with type 2 diabetes were randomized to treatment with insulin
glargine (comparing active vs usual algorithmic titration, and
point-of-care vs laboratory measurement of HbA1c) for a period
of 24 weeks (Kennedy et al. 2006). No unexpected findings in
the frequency or spectrum of adverse events were observed in
this trial, with hypoglycemia being the most frequent serious
adverse event (Table 7). Similar results were reported by Davies
et al. (2005) in a study involving almost 5000 patients with type
2 diabetes treated with insulin glargine for 24 weeks. In this
study 11% of patients reported an adverse event which was
considered possibly related to insulin glargine and the majority
of these were mild injection site reactions.
In the longest clinical trial reported thus far, patients with type
2 diabetes were treated with insulin glargine or NPH insulin for
an initial 1-year period (Massi Benedetti et al. 2003) and
followed for a further 28 months (Kacerovsky-Bielesz et al.
2006). As can be seen in Table 8, the incidence of adverse
events was similar between the two treatment groups. During
the extension study, insulin glargine was well tolerated with
only four patients reporting adverse events that were
considered possibly related to treatment (Kacerovsky-Bielesz
et al. 2006).
Schober et al. (2002) reported on the tolerability of insulin
glargine and NPH insulin as part of basal/bolus regimens
administered for 6 months to 349 children/adolescents (aged
5–16 years) with type 1 diabetes. Both drugs were well
tolerated, but there were fewer serious adverse events in the
insulin glargine group (5.8% vs 13.7%). None required
discontinuation of therapy.
Finally, two clinical trials compared insulin glargine as third-line
therapy with rosiglitazone (Rosenstock et al. 2006) or exenatide
(Heine et al. 2005) in type 2 diabetic patients with poor
glycemic control. Adverse events possibly related to treatment
were significantly more frequent with rosiglitazone (28.6% vs
6.7%;  P<0.0001). Compared with exenatide, insulin glargine
was associated with a significantly lower incidence of
gastrointestinal side effects, most notably nausea (8.6% vs
57.1%;  P<0.001), and vomiting (3.7% vs 17.4%; P<0.001).
Since nausea and vomiting may predispose diabetic patients
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No. of patients Study group
7893 Adults with type 2 diabetes treated with 
insulin glargine
7605 (96.4%) Safety population [7893: patients with no 
data (n=169) or who did not receive treatment
(n=119)]
2737 (35%) Reported at least one AE related to treatment
751 (10%) Reported one AE that was assessed as being
possibly related to insulin glargine
642 (8%)a Reported at least one AE that was classified 
as serious
129 (1.7%) Serious AEs assessed as being possibly
related to insulin glargine and of these only
hypoglycemia occurred in >0.1% of patients
35 (0.5%) Deaths; the majority due to cardiovascular
events and none were assessed as being
caused by insulin glargine
aSerious AEs reported by >0.1% of patients were hypoglycemia (2.1%); cardiac failure
(0.6%); chest pain (0.5%); coronary artery disease (0.5%); cellulitis (0.4%); pneumonia
(0.4%); myocardial infarction (0.3%); transient ischemic attacks (0.2%); cerebrovascular
accident (0.2%). Ninety-five patients (1.2%) discontinued treatment because of a serious AE.
AE, adverse event.
Table 7 | Summary of safety data from a large clinical trial
involving >7000 patients with type 2 diabetes treated
with insulin glargine for 24 weeks (Kennedy et 
al. 2006)
Safety parameter Insulin glargine (n=289) NPH insulin (n=281)
At least one AE 65% 65%
AE possibly related 
to medication
5.5% 7.5%
Injection site reactions 2.4% 3.2%
Metabolic/nutritional AE 1.7% 2.5%
Change in bodyweight +2.01 kg +1.88 kg
Antibodies against IG +0.9%a +5.9%
Antibodies against NPH +0.5%a +6.3%
aStatistically significant difference between IG and NPH.
AE, adverse event; IG, insulin glargine; NPH, neutral protamine hagedorn.
Table 8 | Safety profile in patients with type 2 diabetes treated
with insulin glargine or NPH insulin for 1 year 
(Massi Benedetti et al. 2003)(usually type 1) to ketoacidosis, this is clearly an important
finding, Separately, one case of nausea and vomiting has been
reported in a type 1 diabetic patient treated with insulin glargine
(Dixon & Bain 2005).
Within the published clinical literature the most commonly
discussed tolerability and safety issues associated with the
treatment of diabetic patients with insulin include: symptomatic
hypoglycemia, injection site reactions, possible
immunogenicity, effects on bodyweight, and possible
progression of retinopathy. These will be discussed separately
based mainly on the evidence of the large clinical trials cited in
Tables 3 to 6.
Symptomatic hypoglycemia
Aggressive titration of insulin to achieve tight glycemic control
is hampered by the potential occurrence of hypoglycemic
episodes. Indeed, hypoglycemia is the most frequent acute
complication of intensive insulin therapy in patients with type 1
diabetes (Ratner et al. 2000).
The incidence of symptomatic and/or nocturnal and severe
hypoglycemia was reviewed in the Clinical efficacy section
(Tables 3, 4, and 6). While not all clinical trials demonstrated a
statistically significant advantage for insulin glargine over
comparator insulin regimens (mostly NPH insulin) in patients
with type 1 or type 2 diabetes, there is a clinically significant
trend in favour of glargine. Thus, in the 17 large controlled trials
reviewed in Tables 3, 4, and 6, 14 trials identified a significantly
lower occurrence of hypoglycemia with insulin glargine; two
trials noted no difference between insulin glargine and NPH
insulin. The final trial reported a lower incidence of nocturnal
hypoglycemia with premixed biphasic insulin lispro 25/75
despite a lower incidence of symptomatic hypoglycemia with
insulin glargine (Malone et al. 2005).
Overall, there appears to be a clinically relevant trend toward
fewer hypoglycemic episodes (including nocturnal
hypoglycemia) with insulin glargine compared with more
traditional insulins such as NPH. The low rate of hypoglycemic
episodes has been confirmed in large studies (involving a total
of >10 000 patients) comparing different treatment algorithms
of insulin glargine in patients with type 2 diabetes (Davies et al.
2005; Kennedy et al. 2006) and in a meta analysis comparing
insulin glargine with NPH insulin (Rosenstock et al. 2005).
Injection site reactions
Apart from hypoglycemia, the most common adverse event
reported in clinical trials published to date has been a reaction at
the site of injection; this applies to comparator insulin products
as well as insulin glargine. The type of injection site reaction has
been further subdivided to include: pain hemorrhage, mass, or
“reaction.” Reviewing all the large clinical trials included in Tables
3, 4, and 6 revealed no clinically significant trend with regards  to
this adverse effect, with all authors concluding that the episodes
were mild and did not require discontinuation of treatment. In
four trials, injection site pain was more common in patients
treated with insulin glargine that in those receiving NPH insulin
(Raskin et al. 2000; Ratner et al. 2000; Rosenstock et al. 2001;
Hershon et al. 2004), but in all cases the effect was considered
mild and once again did not require discontinuation of treatment.
There is some evidence that with time and perhaps developing a
better injection technique (regular rotation of the injection site),
local reactions are not a clinical concern. For example, Massi
Benedetti et al. (2003) reported an incidence of injection site
reactions of 3.1% in insulin glargine-treated patients (n=289; one
patient discontinued therapy) and 3.9% in NPH insulin-treated
patients (n=281). A total of 239 patients from the insulin glargine
group entered a long-term follow-up study of up to 28 months’
duration and no adverse events concerning the injection site
were recorded; specifically there were no reports of pain
(Kacerovsky-Bielesz et al. 2006).
In a study involving 349 children/adolescents (aged 5 to 16 years)
treated with insulin glargine or NPH insulin for 6 months there
was no difference between the two treatments with respect to
injection site adverse reactions classified as atrophy, fibrosis,
hemorrhage, mass, pain, or reaction (Schober et al. 2002). It has
been speculated that patients perceive more pain during
subcutaneous administration of acidic solutions (such as insulin
glargine; pH 4.0). In this regard Karges and colleagues (2006)
compared insulin glargine (acidic) with NPH (neutral) in 112
children/adolescents aged 7–21 years with type 1 diabetes.
There was no significant difference in pain perception between
the two treatments and pain scores were also very similar to
those associated with the injection of short-acting regular insulin.
Retinopathy
Diabetes mellitus is a leading cause of blindness in the adult
population and the most effective treatment is prevention by
means of tight control of blood glucose levels and blood
pressure (Powers 2005). Regular eye examinations are essential
for all patients with diabetes mellitus (type 1 or 2) and careful
monitoring is crucial when new therapies are introduced. Initially
it was thought that the high binding affinity of insulin glargine for
insulin-like growth factor (IGF)-1 receptors may adversely impact
the progression of retinopathy in diabetic patients (Chakkarwar &
Manjrekar 2005). However, clinical studies have not observed
any such changes.
The most extensive data for insulin glargine derives from a
retrospective analysis of clinical trials involving data from 2207
patients who were treated with insulin glargine or NPH insulin for
28 to 52 weeks (McKeage & Goa 2001). Overall, the panel of
experts who reviewed the data concluded that there was no
increased risk toward retinopathy with insulin glargine compared
with NPH insulin. While individual studies reported higher rates of
new macular edema and a ≥3-step change in progression of
retinopathy (both using photographic methods) with insulin
glargine, there were no reports of optic disc swelling in any of the
treatment groups (McKeage & Goa 2001). In published studies
reviewed in the clinical sections, there has been no reported
increased risk of development or progression of diabetic
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retinopathy for insulin glargine compared with NPH insulin
(Raskin et al. 2000; Home et al. 2005).
Bodyweight
Good nutritional balance, paying particular attention to
bodyweight, is a prerequisite for optimal treatment 
programs in patients with type 1 and type 2 diabetes 
mellitus. Unfortunately, in patients with type 2 diabetes, 
obesity is a common underlying problem and such patients
frequently fail to adhere to dietary control and exercise
programs/recommendations. Consequently, it is important 
to monitor changes in bodyweight to minimize possible
cardiovascular risk. Weight gain is a common problem
associated with insulin replacement therapy (Chakkarwar 
& Manjrekar 2005). In the case of insulin glargine, changes 
in bodyweight reported in clinical trials were generally 
small with no clinically significant differences between insulin
glargine and NPH insulin in patients with type 2 diabetes. In 
two large studies involving a total of >10 000 patients with 
type 2 diabetes, insulin glargine for 24 weeks resulted 
in an increase in mean bodyweight of between 1 and 2 kg
(Davies et al. 2005; Kennedy et al. 2006). A similar finding 
was documented following 1 year of treatment with insulin
glargine (+2.12 kg vs baseline) in patients with type 2 diabetes
(Massi Benedetti et al. 2003). Interestingly, with continued
treatment for at least a further 28 months no further increase in
bodyweight was observed (+2.02 kg vs baseline) (Kacerovsky-
Bielesz et al. 2006). In contrast, in an observational study
undertaken in Germany involving >12 000 patients suboptimally
treated with oral antidiabetic drugs, body mass index
decreased slightly in patients treated with insulin glargine
compared with those who continued titration with oral therapy.
Insulin antibodies
A possible concern with the administration of a foreign 
protein such as insulin glargine is the potential to induce an
immunogenic response. However, none of the studies 
(16 weeks to >3 years) that assessed antibody levels 
showed any evidence of such a reaction (Pieber et al. 2000; 
Raskin et al. 2000; Ratner et al. 2000; Yki-Järvinen et al. 
2000; Rosenstock et al. 2001; Schober et al. 2002; 
HOE 901/2004 Study Investigators Group 2003; Massi 
Benedetti et al. 2003; Home et al. 2005; Kacerovsky-Bielesz 
et al. 2006).
The majority of these clinical trials reported a similar lack of
effect for insulin glargine and NPH insulin on antibody titers.
However, four trials reported that insulin glargine was
potentially less immunogenic than NPH insulin (Raskin et al.
2000; Yki-Järvinen et al. 2000; Rosenstock et al. 2001; Massi
Benedetti et al. 2003). In the longest study, insulin glargine
administered for ≥28 months did not increase mean insulin
glargine antibody levels or mean human insulin antibody levels
following an initial 52-week comparative study. Indeed, with
time, antibody levels slightly decreased (Kacerovsky-Bielesz et
al. 2006).
Economic evidence
Economic assessments in diabetes can take a variety of
perspectives depending on the type of patient, the healthcare
system/country involved, the scientific/economic question
being tested, and the type of study (RCT vs everyday practice).
With regards to interpretation of such studies it is important to
recognize that findings from one healthcare system may not
necessarily apply to a different healthcare system. In most
clinical scenarios the RCT is the benchmark for establishing
scientific “best evidence,” and there has been a tendency for
health economists to use such trials to perform economic
evaluations. However, the rigidity of RCTs creates limitations
with respect to representing “real world” everyday practice. In
such situations observational studies involving large cohorts of
patients using the test products on a day-by-day basis
provides valuable information about drug usage and its impact
on patients outside the artificial confines of a clinical trial (Dixon
& Peters 2007). For insulin glargine a number of RCTs and
observational economic studies have recently been published
(Table 9).
Type 1 diabetes mellitus
McEwan and colleagues (2007a) compared insulin glargine with
NPH insulin using a sophisticated model incorporating risk
factors from major clinical trials such as the DCCT trial and
Framingham studies. Based on two possible clinical scenarios
(reduced hypoglycemia or reduced HbA1c), cost and health
outcomes for a cohort of 10 000 patients treated for 40 years
were forecast. This model demonstrated significant benefits for
insulin glargine and the incremental cost effectiveness was
found to be similar to that presented in the original NICE
submission, thus reaffirming the overall value for money of
insulin glargine and the significant health benefits that it
provides. Comparable results from a Canadian payer
perspective were reported by Grima and colleagues (2007)
(Table 9).
The two remaining economic analyses with insulin glargine in
patients with type 1 diabetes were comparisons with insulin
detemir—one in the US and one in the UK—and produced very
divergent results. 
Valentine and colleagues (2006) in the US applied economic
data to a single RCT in which insulin detemir was found to
produce significantly less hypoglycemia than insulin glargine.
Costs applied to a Center for Outcomes Research (CORE)
diabetes model highlighted significant health economic
advantages for insulin detemir. In comparison with insulin
glargine, insulin detemir increased quality-adjusted life
expectancy by 0.063 quality-adjusted life-years (QALYs), and
reduced both direct and indirect medical costs. In contrast
Poole et al. (2007) in the UK reported that the total cost of
treatment was 10% lower for insulin glargine compared with
insulin detemir (£132/patient per year; P<0.001). These data
were derived from an observational study involving type 1
diabetic patients treated for at least 6 months with insulin
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Reference Country/healthcare system Economic objective Economic model Results and conclusions
Assessments in patients with type 1 diabetes
McEwan et al. 2007a UK/NHS CE/CU comparison of IG 
and NPH insulin
Simulated outcomes
model using DCCT and
Framingham data with
meta analysis of RCT of
IG vs NPH results
The incremental CE ratio for IG vs
NPH insulin ranged from £2695 to
£10 943; consistently below the 
£20 000/QALY considered cost
effective by the NHS. Compared 
with NPH, IG was highly cost
effective and provided significant
health benefits
Grima et al. 2007 Canada/public payer
perspective
CE/CU comparison of IG 
and NPH insulin
Simulated outcomes
model to which results
from a RCT of IG vs
NPH were incorporated
IG resulted in greater life-years gained
(0.21–0.24) and QALYs (0.17–0.2)
compared with NPH. The weighted
incremental cost per life-year and
QALY gained were $Can18 661 and
$Can20 799. These data provide
strong support for the adoption of 
IG from a Canadian payer view
Poole et al. 2007 UK/NHS Prescription costs and total
cost of treatment or IG 
and ID 
Analysis of treatment
costs (drugs, reagents,
syringes, sharps,
hypoglycemia rescue
medication) for patients
treated with IG (n=625) or
ID (n=268), THIN data
The volume of IG prescribed was
consistently lower with IG than with
ID and the total cost of treatment 
was 10% lower for IG compared 
with ID (£132/patient per year;
P<0.001)
Valentine et al. 2006 US/Medicare CE/CU comparison of IG 
and ID
CORE Diabetes Model
incorporating clinical
data from a single RCT
of IG vs ID 
Compared with IG, ID increased
quality-adjusted life expectancy by
0.063 QALYS, and reduced direct
medical costs by $US2072 and
indirect costs by $US3103
Assessments in patients with type 2 diabetes
McEwan et al. 2007b UK/NHS CE/CU comparison of IG 
and NPH insulin
Simulated outcomes
model using UKPDS
study data, data from
the THIN database and
two meta analyses
comparing IG vs NPH 
The incremental CE ratio for IG 
vs NPH insulin was £10 027/QALY 
in one model and £13 921/QALY
in another; consistently below the 
£20 000/QALY considered cost
effective by the NHS. Compared 
with NPH, IG was highly cost
effective and provides excellent 
value for money for the treatment 
of type 2 diabetes in the UK
Grima et al. 2007 Canada/public payer
perspective
CE/CU comparison of IG 
and NPH insulin
Simulated outcomes
model using UKPDS
data to which results
from a RCT of IG 
vs NPH were
incorporated
IG resulted in greater life-years
gained (0.52–0.59) and QALYs
(0.48–0.52) compared with NPH. 
The weighted incremental cost per
life-year and QALY gained were
$Can8041 and $Can8618. These 
data provide strong support for the
adoption of IG from a Canadian
payer view
Poole et al. 2007 UK/NHS Prescription costs and total
cost of treatment for IG 
and ID
Analysis of treatment
costs (drugs, reagents,
syringes, sharps,
hypoglycemia rescue
medication) for patients
treated with IG (n=977)
or ID (n=334), THIN data
In type 2 diabetics the median cost
for antidiabetic therapy was 28.1%
lower in patients treated with IG 
than in those treated with ID 
(£1014 vs £1410/patient per year;
P<0.001)
Ray et al. 2007 US/general practice CE/CU comparison of IG 
and biphasic insulin aspart
Mix 30
Costs applied to the
INITIATE RCT (IG,
n=116; Mix 30, n=117)
and input into a
validated Markov/Monte-
Carlo simulation model
This study suggests that long-term
treatment with biphasic aspart 
Mix 30 in insulin-naïve type 2 
diabetic patients as part of a 
triple-therapy regimen may have
economic advantages over IG. 
The authors acknowledge the
limitations of the clinical trial which
was of short duration and included 
a relatively young cohort of patients
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glargine or insulin detemir and who were included on the THIN
database. Data were extracted from the same time period to
avoid biases occurring as a result of changes in the rapidly
evolving nature of diabetes-related clinical practice.
Interestingly, the cost of hypoglycemia rescue medication was
25% lower with insulin glargine (P=0.052). Overall the authors
calculated that based on these findings, treating 1000 patients
for 1 year with insulin glargine would save £132 000 compared
with insulin detemir.
Warren and colleagues (2004) assessed the economic
evaluation presented with the original NICE submission of
insulin glargine and published revised cost-effectiveness
figures. They recognize that the model is highly sensitive to
clinical assumptions such as the amount of utility gained by
reducing patients’ fear of hypoglycemia. Overall they concluded
that compared with NPH insulin, insulin glargine is effective in
reducing the incidence of nocturnal hypoglycemia, but since
there does not appear to be any improvement in long-term
glycemic control, insulin glargine is unlikely to reduce the
incidence of long-term microvascular and cardiovascular
complications associated with the disease. This latter
conclusion can be questioned based on more recent findings
with more aggressive treatment algorithms, and it will be
interesting to see whether longer-term therapy with insulin
glargine can impact microvascular/cardiovascular endpoints
beyond that achieved with conventional insulins.
Type 2 diabetes mellitus
McEwan and colleagues (2007) compared insulin glargine with
NPH insulin using a sophisticated model incorporating evidence
from the UK Prospective Diabetes Study to simulate disease
progression, data from the THIN database for patient
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table continued…
Reference Country/healthcare system Economic objective Economic model Results and conclusions
Lechleitner et al. 2005 Austria/general practice Total cost of treatment with 
IG and conventional insulins.
Treatment and dosage were
based on everyday practice
Simulated outcomes
model using DCCT and
Framingham data with
meta analysis of RCT
of IG vs NPH results
Observational study comparing IG
with conventional insulin therapy to
which appropriate costs were applied
Bullano et al. 2006 US/general practice Comparison of the cost of
managing hypoglycemia in 
inpatients treated with IG 
or a premixed fixed dose
combination product
An observational
analysis involving
patients treated with 
IG (n=1212) or a
premixed fixed-dose
combination product
(n=1103) identified
using a claims
database. Cost of
managing
hypoglycemia 
in patients
Type 2 diabetic patients recently
starting IG therapy had a lower rate
of hypoglycaemia than patients
using fixed-dose insulin 
combination products 
(7 vs 13.8 patients/year; P=0.027). 
The authors calculated that
treatment of 15 patients with IG
would avoid one hypoglycemic
event per year compared with the
premixed combination products
Rosenstock et al. 2006 US/general practice To compare the total cost of
maintaining glycemic control
in patients using IG or
rosiglitazone in a triple 
therapy regimen
Cost analysis applied 
to a RCT comparing 
IG (n=105) and
rosiglitazone (n=112) 
in triple therapy
regimens
The cost of maintaining glycemic
control was significantly lower with
IG than with rosiglitazone (IG saved
$US235 over a period of 24 weeks).
Furthermore the authors calculated
that the mean cost per 1%
reduction in HbA1c was $US824 for
IG and $US1062 for rosiglitazone;
an important finding given that
medical resource utilization may
further decrease as a result of
improved glycemic control
Meneghini et al. 2006 US/general practice To compare the total cost of
maintaining glycemic control
in patients using IG or
pioglitazone added to oral
monotherapy
Cost analysis applied
to a RCT comparing 
IG (n=118) and
pioglitazone (n=112) 
as add-on therapy 
IG added to monotherapy in
patients with poorly controlled type
2 diabetes improved clinical
outcomes such as glycemic control
and quality of life. The estimated
mean total cost of glycemic control
over 48 weeks was $US379 less for 
IG-treated patients ($US1721 
vs $US2100 for pioglitazone)
CE, cost-effectiveness evaluation; CORE, Center for Outcomes Research; CU, cost-utility evaluation; DCCT, Diabetes Control and Complications Trial; ID, insulin detemir; IG, insulin glargine;
NHS, National Health Service; NPH, neutral protamine hagedorn; OAD, oral antidiabetic drug; QALY, quality-adjusted life-year; RCT, randomized clinical trial; THIN, The Health Improvement
Network; UKPDS, UK Prospective Diabetes Study.characteristics, and appropriate outcomes results from pivotal
clinical trials. The incremental cost-effectiveness ratio for 
insulin glargine versus NPH insulin was £10 027/QALY in one
model (based on hypoglycemia) and £13 921/QALY in another
(based on HbA1c); consistently below the £20 000/QALY
considered cost effective by NICE. The authors concluded that
compared with NPH, insulin glargine was highly cost 
effective and provides excellent value for money for the
treatment of type 2 diabetes in the UK. These findings were
reinforced by Grima et al. (2007) who undertook a similar
analysis, but from a payer perspective, in Canada (Table 9).
Poole and colleagues (2007), again using observational data
from the THIN database, reported that in type 2 diabetics the
median cost for antidiabetic therapy was 28.1% lower in
patients treated with insulin glargine compared with those
treated with insulin detemir (£1014 vs £1410/patient per year;
P<0.001).
Bullano and colleagues (2006) in the US reported that type 2
diabetic patients recently starting glargine therapy had a lower
rate of hypoglycemia than patients using fixed-dose insulin
combination products (7 vs 13.8 patients/year; P=0.027) and
calculated that treatment of 15 patients with insulin glargine
would avoid one hypoglycemic event per year compared with the
premixed combination insulins.
In a US study long-term treatment with biphasic aspart Mix 30 in
insulin-naïve type 2 diabetic patients as part of a triple-therapy
regimen was more cost effective than insulin glargine, with an
incremental cost-effectiveness ratio of $US46 533 per QALY. The
authors acknowledge the limitations of the clinical trial which was
of short duration and included a relatively young cohort of
patients (Ray et al. 2007). Lechleitner and colleagues (2005) found
that total daily costs were similar for insulin glargine and
conventional insulins, although the glargine group used
significantly lower doses of insulin and required fewer blood
glucose test strips.
Finally, in two clinical trials the total cost of achieving glycemic
control was lower for insulin glargine than for rosiglitazone
(Rosenstock et al. 2006) or pioglitazone (Meneghini et al. 2006) as
add-on therapy in patients with type 2 diabetes poorly controlled
with oral therapy. 
Clinical value
Diabetes mellitus is a chronic disease associated with high
morbidity and mortality as a result of microvascular and
macrovascular complications. Today it represents a major public
health concern of almost epidemic proportions and this picture is
forecast to worsen as patient populations become older and are
associated with a greater prevalence of risk factors (Chan &
Abrahamson 2003; Powers 2005). This will increase the burden on
health services, which are already under pressure. It almost goes
without saying that any intervention that can improve patient care
and reduce clinic/hospital visits will not only relieve some of this
burden, it will also likely have a positive impact on patient QOL
and wellbeing.
The Diabetes Control and Complications Trial (DCCT Research
Group 1993) provided convincing evidence that tight and
sustained management of glycemia using an intensive therapy
regimen and regular follow-up/monitoring, reduces both the
development and progression of microvascular complications.
These findings form the basis for most treatment guidelines used
in the care of diabetic patients. One of the biggest challenges
facing the physician and patient when using intensive insulin
regimens is to achieve optimal glycemic control without provoking
episodes of hypoglycemia which could potentially be fatal. 
Hypoglycemia is thought to occur at times corresponding with
peak plasma insulin concentrations, and insulin glargine with its
relatively flat plasma concentration-versus-time profile, with no
pronounced peaks over 24 hours, may therefore have an
advantage. It might also facilitate a more physiologic approach to
diabetes management with basal insulin glargine providing a
constant level of insulin throughout the day, and bolus insulin
being used to provide prandial cover. 
In the setting of type 1 diabetes, basal/bolus treatment with
insulin glargine (once daily) has proven to be at least as effective
as conventional once- or twice- daily treatment with NPH insulin
with a trend toward less hypoglycemia. This evidence was
reviewed by NICE in the UK (NICE 2002) which concluded:
“On the balance of effectiveness and cost-effectiveness
evidence, insulin glargine, which has a peakless action profile, is
also recommended as a long-acting preparation for people with
type 1 diabetes; some studies in this review show significantly
lower FBG with insulin glargine than isophane (NPH) insulin and
others suggest that people on insulin glargine may experience
fewer hypoglycemic events than people receiving once-daily
isophane (NPH) insulin.”
More recent clinical trials have confirmed these findings in studies
of long duration and added to our understanding of the value of
insulin glargine showing that:
• it can be administered at other times of the day with equal
effect (the initial recommendation was for it to be given 
at bedtime)
• it is effective and well tolerated in children and adolescents
• it is a suitable replacement for continuous subcutaneous
insulin infusions during pump-free periods associated with
pump malfunction, adverse effects, or physical activity.
Type 2 diabetes has traditionally been treated in a stepwise
manner with lifestyle modifications such as diet and exercise
being a cornerstone of day-to-day management. If this fails to
achieve the desired level of glycemic control, then oral
antidiabetic drugs can be introduced (alone or in combination).
Insulin has generally only been considered if the above steps fail.
Insulin glargine has been studied in a number of large clinical trials
involving patients poorly controlled by lifestyle changes and oral
antidiabetic therapy, and it was shown to be at least as effective
as NPH insulin with the clinically important advantage of causing
significantly fewer episodes of nocturnal hypoglycemia.
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Economic analyses with insulin glargine have confirmed the
findings of the original NICE assessment, and economic models
applied to UK and Canadian healthcare systems have
demonstrated its cost effectiveness relative to NPH insulin in
patients with type 1 and type 2 diabetes. Equally important, a
number of studies have shown that insulin glargine has a positive
impact on patient satisfaction, wellbeing, and other measures of
QOL. In this regard it was shown to be significantly superior to
NPH insulin in type 1 diabetes, and to pioglitazone and
rosiglitazone in type 2 diabetes.
In summary, there is now a wealth of evidence, including official
recommendations, well-controlled clinical trials, and large
observational studies in everyday practice highlighting the
suitability of insulin glargine as a first-line choice as a 
basal insulin replacement in patients with type 1 diabetes mellitus,
including children and adolescents. There is also convincing
evidence for its efficacy and safety in patients with type 2 disease
who require insulin treatment to achieve glycemic control. 
Future studies should be directed toward establishing the efficacy
and safety of insulin glargine in the long term since it is a 
life-long therapy for most patients. It will also be interesting to 
see whether the potential for more intense glycemic control
correlates with a significant delay in the progression of
microvascular/macrovascular complications and improves 
long-term survival rates. Results from long-term studies
assessing cardiovascular risk/outcomes in large cohorts of
patients, such as ORIGIN (Skyler 2004) and HEART2D (Milicevic
et al. 2005) are awaited with interest.
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